Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease.


Journal

BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391

Informations de publication

Date de publication:
11 2021
Historique:
received: 27 05 2021
accepted: 18 09 2021
entrez: 16 11 2021
pubmed: 17 11 2021
medline: 31 12 2021
Statut: ppublish

Résumé

The prevalence of type 2 diabetes mellitus (T2DM) is higher in peripheral artery disease (PAD) than in coronary artery disease (CAD) patients, and PAD overall confers higher cardiovascular risk than CAD. How cardiovascular risk compares between PAD and CAD patients when analyses are stratified by the presence of type 2 diabetes is unclear and is addressed in the present study. We prospectively recorded major cardiovascular events (MACE; ie, cardiovascular death, myocardial infarction or stroke) over 10.0±4.7 years in 923 patients with stable CAD, of whom 26.7% had T2DM and in 292 patients with PAD, of whom 42.1% had T2DM. Four groups were analyzed: CAD patients without diabetes (CAD/T2DM-; n=677), CAD patients with T2DM (CAD/T2DM+; n=246), PAD patients without diabetes (PAD/T2DM-; n=169) and PAD patients with T2DM (PAD/T2DM+; n=123). The event rate for MACE increased over our four investigated groups: it was lowest in CAD/T2DM- patients (2.52 events per 100 person-years). It was significantly higher in CAD/T2DM+ patients (3.96 events per 100 person-years; p<0.001), in PAD/T2DM- patients (3.68 events per 100 person-years; p=0.022), and in PAD/T2DM+ patients (7.10 events per 100 person-years; p<0.001), who in turn were at a higher risk than CAD/T2DM+ or PAD/T2DM- patients (p=0.001 and p<0.001, respectively). Cox regression analysis after multivariate adjustment showed that the presence of T2DM (HR=1.44 (95% CI 1.09 to 1.92); p=0.012) and the presence of PAD versus CAD (HR=1.48 (95% CI 1.15 to 1.91); p=0.002) were mutually independent predictors of cardiovascular events. In conclusion, our data show that T2DM as well as the presence of PAD versus CAD are mutually independent predictors of MACE. Patients with both PAD and T2DM are at an exceedingly high risk of cardiovascular events.

Identifiants

pubmed: 34782334
pii: 9/2/e002407
doi: 10.1136/bmjdrc-2021-002407
pmc: PMC8593703
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Diabetologia. 2004 Jan;47(1):145-6
pubmed: 14676943
Circulation. 1994 Nov;90(5):2230-5
pubmed: 7955178
J Am Coll Cardiol. 2011 Mar 8;57(10):1220-5
pubmed: 21371639
Circulation. 2016 Jun 14;133(24):2459-502
pubmed: 27297342
Eur Heart J Cardiovasc Pharmacother. 2018 Jan 1;4(1):25-35
pubmed: 28444162
Diabetes Care. 2018 Jan;41(Suppl 1):S3
pubmed: 29222370
Diabetes Res Clin Pract. 2018 Apr;138:81-89
pubmed: 29421310
J Clin Endocrinol Metab. 2005 Oct;90(10):5698-703
pubmed: 16091486
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
Eur J Clin Invest. 2017 Nov;47(11):819-828
pubmed: 28804899
J Clin Endocrinol Metab. 2020 Nov 1;105(11):
pubmed: 32785694
Eur Heart J. 2013 Aug;34(31):2444-52
pubmed: 23625211
Clin Epidemiol. 2019 May 23;11:419-428
pubmed: 31191034
Eur Heart J. 2013 Jul;34(28):2159-219
pubmed: 23771844
Int J Prev Med. 2019 Jun 07;10:106
pubmed: 31360353
Am J Cardiol. 2019 Jun 15;123(12):1893-1899
pubmed: 31014542
Diab Vasc Dis Res. 2015 Mar;12(2):146-9
pubmed: 25616706
Diabetes Care. 2014 Jun;37(6):1636-42
pubmed: 24705616
J Am Coll Cardiol. 2002 Sep 4;40(5):954-60
pubmed: 12225722
Diabetes Care. 2005 Jan;28(1):101-7
pubmed: 15616241
BMC Cardiovasc Disord. 2019 Oct 24;19(1):234
pubmed: 31651241
Int J Cardiol. 2013 Aug 10;167(3):776-80
pubmed: 22483261
Eur J Prev Cardiol. 2015 Mar;22(3):317-25
pubmed: 24398369
Atherosclerosis. 2018 Dec;279:32-37
pubmed: 30399464
Circ Res. 2015 Apr 24;116(9):1509-26
pubmed: 25908725
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Int J Cardiol. 2018 Mar 15;255:69-73
pubmed: 29290420

Auteurs

Lukas Sprenger (L)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria.
Department of Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

Arthur Mader (A)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria.
Department of Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

Barbara Larcher (B)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria.
Department of Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

Maximilian Mächler (M)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria.
Department of Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

Alexander Vonbank (A)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria.
Department of Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

Daniela Zanolin-Purin (D)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

Andreas Leiherer (A)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

Axel Muendlein (A)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

Heinz Drexel (H)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.
Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Department of Medicine, County Hospital Bregenz, Bregenz, Vorarlberg, Austria.

Christoph H Saely (CH)

VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria christoph.saely@icloud.com.
Department of Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Vorarlberg, Austria.
Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH